STOCK TITAN

Longeveron Inc - LGVN STOCK NEWS

Welcome to our dedicated page for Longeveron news (Ticker: LGVN), a resource for investors and traders seeking the latest updates and insights on Longeveron stock.

Longeveron Inc (LGVN) is a clinical-stage biotechnology pioneer advancing regenerative therapies through mesenchymal stem cell research. This page provides centralized access to official news and press releases for investors tracking the company's progress in treating conditions like hypoplastic left heart syndrome (HLHS), Alzheimer's disease, and aging-related frailty.

Discover timely updates on clinical trial developments, regulatory milestones including FDA designations, and strategic partnerships. Our curated collection offers investors and researchers a reliable resource for understanding Longeveron's investigational product Lomecel-B and its applications in cellular therapeutics.

Key content includes updates on pediatric cardiac care advancements, neurodegenerative disease research breakthroughs, and manufacturing developments for allogeneic therapies. Bookmark this page to stay informed about critical updates affecting Longeveron's position in the regenerative medicine sector.

Rhea-AI Summary

Longeveron has announced the election of Roger Hajjar, MD, to its Board of Directors. Dr. Hajjar, an acclaimed scientist in cardiac gene therapy and current Director of the Gene and Cell Therapy Institute at Mass General Brigham, brings extensive expertise to the company. His contributions in gene therapy have initiated numerous clinical trials and his methodologies are globally implemented. This move is part of Longeveron's strategy to refresh its Board with experienced leaders to enhance its ongoing therapeutic developments, including Lomecel-B™. Dr. Hajjar's background includes 500 publications and various awards. His academic credentials include degrees from Johns Hopkins and Harvard Medical School, with significant professional contributions at Massachusetts General Hospital, Mount Sinai, and Flagship Pioneering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.65%
Tags
management
-
Rhea-AI Summary

Longeveron has raised $4.4 million in gross proceeds from the exercise of existing warrants to purchase 1,697,891 shares of its Class A common stock at $2.35 per share, originally issued in April 2024. The exercise was facilitated by H.C. Wainwright & Co. as the exclusive placement agent. In return, Longeveron has issued new unregistered warrants for 3,395,782 shares, exercisable at $2.50 per share for 24 months. The company plans to use the net proceeds to fund the clinical and regulatory development of Lomecel-B™ for conditions like HLHS and Alzheimer’s, as well as for general corporate purposes. The new warrants were issued in a private placement and are not registered under the Securities Act.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.36%
Tags
none
-
Rhea-AI Summary

Longeveron, a clinical stage biotech firm listed on NASDAQ as LGVN, will participate in the Virtual Life Sciences Investor Forum on June 20, 2024. The company focuses on developing cellular therapies for critical and aging-related conditions, such as hypoplastic left heart syndrome (HLHS) and Alzheimer’s disease. The event includes a fireside chat scheduled at 10:30 a.m. ET on June 20, 2024. The webcast can be accessed via the 'Events and Presentations' section of Longeveron's website, with a replay available for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.76%
Tags
conferences
Rhea-AI Summary

Longeveron announced the exercise of warrants for $4.4 million in gross proceeds. These warrants, issued in April 2024, allowed the purchase of 1,697,891 Class A common stock shares at $2.35 per share. H.C. Wainwright & Co. is the offering's exclusive placement agent. In exchange for immediate cash exercise and a $0.125 fee per new warrant, Longeveron will issue new warrants for 3,395,782 Class A common stock shares at $2.50 per share, valid for 24 months. The proceeds will fund clinical and regulatory development of Lomecel-B™, regulatory approvals, capital expenditures, and general corporate purposes. The new warrants are offered under Section 4(a)(2) of the Securities Act and are not registered under state securities laws.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.76%
Tags
none
-
Rhea-AI Summary

Longeveron announces the completion of an investigator meeting for its ELPIS II Phase 2b clinical trial evaluating Lomecel-B™ as a treatment for Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric heart defect. The trial is on track to complete enrollment of 38 patients by the end of 2024. Multiple nationally recognized children's treatment centers are participating. Phase 1 results showed a 100% transplant-free survival rate up to five years, compared to a 20% historical mortality rate. The trial aims to further evaluate the safety and efficacy of Lomecel-B™.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.64%
Tags
-
Rhea-AI Summary

Longeveron, a clinical stage biotechnology company (NASDAQ: LGVN), announced its participation in the Emerging Growth Virtual Conference on June 12-13, 2024. The company will present on June 12 at 1:45 p.m. ET. The presentation will be webcast and accessible via the 'Events and Presentations' section of Longeveron's website. A replay will be available for 180 days post-conference. Questions can be submitted in advance or during the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
conferences
Rhea-AI Summary

Longeveron announced the launch of a new contract development and manufacturing business at its 15,000 sq. ft. GMP facility. The company signed its first contract with Secretome Therapeutics, a biotechnology firm working on neonatal mesenchymal stem cell-based therapeutics. This new business line is expected to generate $4-5 million in annual revenues. Longeveron aims to leverage its expertise and capacity to advance other pharmaceutical programs. The company continues to focus on its lead therapeutic candidate, Lomecel-B, for multiple conditions, including hypoplastic left heart syndrome and Alzheimer's disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.45%
Tags
none
-
Rhea-AI Summary

Longeveron (NASDAQ: LGVN), a clinical-stage regenerative medicine biotech, will attend the BIO International Convention from June 3-6, 2024, in San Diego. At the event, Longeveron's management will meet with global pharma executives to discuss partnerships and strategic opportunities for its Alzheimer's disease program. Their lead candidate, Lomecel-B™, showed promising results in the Phase 2a CLEAR MIND trial, achieving primary safety and secondary efficacy endpoints. The trial indicated Lomecel-B™ could slow or prevent disease worsening in mild Alzheimer's patients. These findings will be presented at the 2024 Alzheimer's Association International Conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
conferences
-
Rhea-AI Summary

Longeveron (NASDAQ: LGVN) reported its Q1 2024 financials, highlighting significant progress in clinical trials for its lead candidate, Lomecel-B™. Notably, the Phase 2b trial for HLHS is on track for completion by 2024 end. Data from a Phase 2a Alzheimer's trial will be presented at the 2024 Alzheimer’s Conference, showing promising results. Financials show a 96% revenue increase to $0.5 million, driven by the Bahamas Registry Trial, and an 8% reduction in operating expenses. The company raised $11.4 million in April, bolstering its cash reserves to $2.3 million, which is expected to fund operations through Q4 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.6%
Tags
Rhea-AI Summary

Longeveron Inc. (NASDAQ: LGVN) announced planned transitions on its Board of Directors, welcoming Richard Kender, a retired Merck executive, and nominating Dr. Roger Hajjar and Neha Motwani as new board candidates. Existing directors Joshua Hare and Ursula Ungaro are up for re-election. Jeffrey Pfeffer and Cathy Ross have resigned voluntarily. These changes aim to bring in new, experienced leaders to enhance Longeveron's therapeutic development programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.65%
Tags
management
Longeveron Inc

Nasdaq:LGVN

LGVN Rankings

LGVN Stock Data

21.84M
13.92M
7.04%
8.64%
3.75%
Biotechnology
Pharmaceutical Preparations
Link
United States
MIAMI